The circulating level of C-reactive protein (CRP) is a strong predictor of cardiovascular disease and endothelial dysfunction. However, it is unknown whether CRP plays a causal role in these processes. We have discovered that CRP inhibits both endothelial NO synthase (eNOS) gene expression and processes regulating eNOS enzymatic activity, thereby decreasing the production of a key antiatheroslerotic molecule. The OBJECTIVE of the proposed research is to determine the mechanisms by which CRP downregulates eNOS expression and function, and the specific role of CRP in endothelial dysfunction and atherogenesis. In preliminary studies, CPR attenuated eNOS promoter activity by 90%.
Aim 1 is to determine the mechanism by which CRP downregulates eNOS gene transcription. CRP-responsive regulatory elements will be delineated by mutagenesis of the eNOS promoter, and relevant nuclear proteins will be identified in electrophoretic mobility shift assays. We also have found that brief (15 min) CRP exposure fully prevents agonist stimulation of eNOS.
Aim 2 is to determine the basis by which CRP attenuates the capacity to activate the enzyme. Studies will assess CRP effects on kinase cascades upstream of eNOS, eNOS phosphorylation, and intracellular [Ca2+].
Aim 3 is to determine the role of IgG Fcgamma receptors (FcgammaR),which bind CRP in other paradigms, and associated signaling molecules in CRP actions on eNOS. In initial studies, CRP effects on eNOS were mimicked by aggregated IgG; in addition, in isolated mouse carotid arteries eNOS expression fell by 89% with 24h CRP exposure, and 15min CRP treatment caused full blockade of acetylcholine-stimulated cGMP accumulation. As such, loss-of-function studies are feasible using arteries from FcgammaR-null mice. We have also shown that endothelial cells express both isoforms of SHIP (SH2 domain-containing inositol 5-phosphatase), which is recruited to inhibitory FcgammaRIIB in immune effector cells and which hydrolyzes PIP3, thereby blunting PI3 kinase action. The role of SHIP-l/2 will be determined in studies of SHIP activation by CRP and SHIP loss-of-function using dominant negative mutants.
Aim 4 is to determine the impact of CRP on eNOS expression, endothelial function an d atherogenesis in transgenic mice with diet-regulated CRP expression directed by the PEPCK promoter. Carotid blood flow responses and reendothelialization following electric injury will be tested at varying CRP levels. The impact of CRP on atherogenesis wall be determined an crosses of PEPCK-CRP and apoE mice. By meeting these aims, the proposed research will provide mechanistic links between CRP and endothelial dysfunction and vascular disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL075473-03
Application #
6982804
Study Section
Experimental Cardiovascular Sciences Study Section (ECS)
Program Officer
Srinivas, Pothur R
Project Start
2003-12-23
Project End
2007-11-30
Budget Start
2005-12-01
Budget End
2006-11-30
Support Year
3
Fiscal Year
2006
Total Cost
$342,752
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Pediatrics
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Shaul, Philip W (2015) Role of the endothelium in the metabolic syndrome: IIB or not IIB. Am J Med Sci 349:3-5
Tanigaki, Keiji; Vongpatanasin, Wanpen; Barrera, Jose A et al. (2013) C-reactive protein causes insulin resistance in mice through Fc? receptor IIB-mediated inhibition of skeletal muscle glucose delivery. Diabetes 62:721-31
Sundgren, Nathan C; Zhu, Weifei; Yuhanna, Ivan S et al. (2011) Coupling of Fc? receptor I to Fc? receptor IIb by SRC kinase mediates C-reactive protein impairment of endothelial function. Circ Res 109:1132-40
Ramesh, Sangeetha; Morrell, Craig N; Tarango, Cristina et al. (2011) Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via *2GPI and apoER2. J Clin Invest 121:120-31
Tanigaki, Keiji; Mineo, Chieko; Yuhanna, Ivan S et al. (2009) C-reactive protein inhibits insulin activation of endothelial nitric oxide synthase via the immunoreceptor tyrosine-based inhibition motif of FcgammaRIIB and SHIP-1. Circ Res 104:1275-82
Park, Kyung-Woo; Kwon, Yoo-Wook; Cho, Hyun-Jai et al. (2008) G-CSF exerts dual effects on endothelial cells--opposing actions of direct eNOS induction versus indirect CRP elevation. J Mol Cell Cardiol 45:670-8
Schwartz, Randall; Osborne-Lawrence, Sherri; Hahner, Lisa et al. (2007) C-reactive protein downregulates endothelial NO synthase and attenuates reendothelialization in vivo in mice. Circ Res 100:1452-9
Vongpatanasin, Wanpen; Thomas, Gail D; Schwartz, Randall et al. (2007) C-reactive protein causes downregulation of vascular angiotensin subtype 2 receptors and systolic hypertension in mice. Circulation 115:1020-8
Mineo, Chieko; Shaul, Philip W (2006) Circulating cardiovascular disease risk factors and signaling in endothelial cell caveolae. Cardiovasc Res 70:31-41
Mineo, Chieko; Gormley, Andrew K; Yuhanna, Ivan S et al. (2005) FcgammaRIIB mediates C-reactive protein inhibition of endothelial NO synthase. Circ Res 97:1124-31